CollPlant Biotechnologies to Present at H.C. Wainwright Global Investment Conference.

CollPlant Biotechnologies, a regenerative and aesthetics medicine company, announced that senior management will participate in the 27th Annual H.C. Wainwright Global Investment Conference. Investors can request one-on-one meetings with CollPlant through their H.C. Wainwright representative or email [email protected]. The company is focused on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics, with products based on its rhCollagen technology.

CollPlant Biotechnologies (NASDAQ: CLGN), a leading company in regenerative and aesthetics medicine, has announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference. The event will take place on September 8-9, 2025, at the Lotte New York Palace Hotel in New York City. Senior management will be available for one-on-one meetings with investors, which can be arranged through H.C. Wainwright representatives or via email at [meetings@hcwco.com](mailto:meetings@hcwco.com).

CollPlant Biotechnologies specializes in 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. The company's flagship technology is its non-animal-derived recombinant human collagen (rhCollagen), which is used to develop innovative products in these fields. Recent advancements include the completion of preclinical testing for a photocurable dermal filler and the development of regenerative breast implants. These products are designed to meet growing demand for innovative aesthetic solutions and address unmet clinical needs.

In the second quarter of 2025, CollPlant reported financial results with GAAP revenues of $179,000, compared to $249,000 in the same period last year. The decrease was primarily due to a reduction in sales of rhCollagen-based products. However, the company achieved a $2 million milestone payment from AbbVie, contributing to a 537.1% year-over-year increase in revenue to $2.23 million. The company also raised $3.6 million through a registered direct offering, providing financial flexibility for future initiatives.

CollPlant's participation in the H.C. Wainwright Global Investment Conference offers investors an opportunity to learn more about the company's latest developments, product pipeline, and financial performance. The event is expected to attract a diverse range of investors, including institutional investors, hedge funds, and private equity firms.

References:

[1] https://www.stocktitan.net/news/CLGN/coll-plant-to-participate-in-the-upcoming-27th-annual-h-c-wainwright-k8i99cg2xkpz.html
[2] https://seekingalpha.com/news/4487367-collplant-biotechnologies-non-gaap-eps-of-0_33-revenue-of-2_23m-misses-by-0_31m
[3] https://www.prnewswire.com/news-releases/collplant-biotechnologies-reports-2025-second-quarter-financial-results-and-provides-corporate-update-302534476.html